Connect Biopharma Holdings Limited CNTB · SEC Filings

64

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discov...

Price0.7503

Market Cap47.23 M

Float49.07 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Connect Biopharma Announces Positive Phase 2 Data for Rademikibart in COPD

Sep 30, 2026

8-K

Connect Biopharma Announces Positive Preliminary Topline Data from Global Phase 2 Study of Rademikibart in Asthma

Sep 15, 2026

8-K

Connect Biopharma Reports Q2 2026 Financial Results and Progress on Rademikibart Clinical Programs

Aug 12, 2026

8-K

Connect Biopharma Reports Q1 2026 Financial Results and Business Update

May 12, 2026

8-K

Connect Biopharma Announces Continuation of Phase 2 Seabreeze STAT Studies Following Interim Analysis

Apr 23, 2026

8-K

Connect Biopharma Reports 2025 Financial Results and Provides Business Update on Rademikibart

Mar 31, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

11,250,000 American Depositary Shares-

Mar 19, 2021

Registrations

TYPE

HEADLINE

FILED AT

F-3

SHARE RESALE REGISTRATION

May 15, 2026

POS AM

Form POS AM - Post-Effective amendments for registration statement

Sep 10, 2025

F-6 POS

Form F-6 POS - Post-effective amendments for immediately effective filing

Jul 18, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 10, 2025

F-3

June 2025 Shelf & ATM | Float: 14,263,455 | Amount sold to date: $0

Jun 10, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 1, 2022

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Qiming Managing Directors Fund V, L.P. (Filed by)

Nov 3, 2026

SCHEDULE 13G

BML Investment Partners, L.P. (Filed by)

Oct 6, 2026

4

Xanthopoulos Kleanthis Gabriel (Reporting)

Oct 1, 2026

4

LIU JEAN I (Reporting)

Oct 1, 2026

SCHEDULE 13G/A

Ikarian Capital, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

Wei Zheng (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT